Suzhou-based startup AllianThera Biopharma has announced the first patient dosing in a global Phase I clinical study for its investigational drug ATB102. The trial, a randomized, double-blinded, placebo-controlled, dose-escalation study, is designed to evaluate the safety, tolerability, and pharmacokinetics of ATB102 in healthy subjects.
Drug Mechanism and Innovation
ATB102 is an intestinally enriched aryl hydrocarbon receptor (AHR) agonist being developed to treat inflammatory bowel diseases (IBDs). Unlike other approved or investigational IBD biologics and small molecule drugs, ATB102 not only promotes and maintains immune homeostasis but also enhances the repair function of the intestinal mucosal barrier. This dual action provides anti-fibrotic and antioxidant effects, positioning ATB102 as a potentially novel therapeutic option for IBD patients.-Fineline Info & Tech
Leave a Reply